Paolo Spagnolo

List of Publications by Year
in descending order

99 papers	4,610 citations	125106 35 h-index	145109 60 g-index
100 all docs	100 docs citations	100 times ranked	5761 citing authors

#	Article	IF	Citations
1	Detection and Early Referral of Patients With Interstitial Lung Abnormalities. Chest, 2022, 161, 470-482.	0.4	26
2	The clinical relevance of lymphocyte to monocyte ratio in patients with Idiopathic Pulmonary Fibrosis (IPF). Respiratory Medicine, 2022, 191, 106686.	1.3	4
3	Lung Microbiome in Idiopathic Pulmonary Fibrosis and Other Interstitial Lung Diseases. International Journal of Molecular Sciences, 2022, 23, 977.	1.8	14
4	Brief communication: Chest radiography score in young COVID-19 patients: Does one size fit all?. PLoS ONE, 2022, 17, e0264172.	1.1	2
5	Aetiopathogenesis, molecular determinants and immunological features. , 2022, , 25-40.		2
6	Integrating Clinical Probability into the Diagnostic Approach to Idiopathic Pulmonary Fibrosis: An International Working Group Perspective. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 247-259.	2.5	15
7	Thoracic Involvement in Systemic Autoimmune Rheumatic Diseases: Pathogenesis and Management. Clinical Reviews in Allergy and Immunology, 2022, 63, 472-489.	2.9	13
8	RNA Sequencing of Epithelial Cell/Fibroblastic Foci Sandwich in Idiopathic Pulmonary Fibrosis: New Insights on the Signaling Pathway. International Journal of Molecular Sciences, 2022, 23, 3323.	1.8	11
9	Drug-induced interstitial lung disease. European Respiratory Journal, 2022, 60, 2102776.	3.1	33
10	Sarcoidosis: principles of diagnosis. , 2022, , 57-74.		1
11	Pathologic comparison of conventional video-assisted thoracic surgical (VATS) biopsy versus non-intubated/â€œawakeâ€•biopsy in fibrosing interstitial lung diseases. Respiratory Medicine, 2022, 195, 106777.	1.3	3
12	On Target: CYFRA 21-1 as an Idiopathic Pulmonary Fibrosis Biomarker. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 1376-1377.	2.5	1
13	Comorbidities of sarcoidosis. Annals of Medicine, 2022, 54, 1014-1035.	1.5	24
14	Pulmonary adverse events following immune checkpoint inhibitors. Current Opinion in Pulmonary Medicine, 2022, 28, 391-398.	1.2	9
15	Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs). Annals of the Rheumatic Diseases, 2021, 80, 143-150.	0.5	120
16	The DIAMORFOSIS (DIAgnosis and Management Of lung canceR and FibrOSIS) survey: international survey and call for consensus. ERJ Open Research, 2021, 7, 00529-2020.	1.1	22
17	Chest radiography or computed tomography for COVID-19 pneumonia? Comparative study in a simulated triage setting. European Respiratory Journal, 2021, 58, 2004188.	3.1	47
18	Arrhythmias in Cardiac Sarcoidosis Bench to Bedside. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e009203.	2.1	14

#	Article	IF	Citations
19	The case of methotrexate and the lung: Dr Jekyll and Mr Hyde. European Respiratory Journal, 2021, 57, 2100079.	3.1	10
20	Prognostic role of MUC5B rs35705950 genotype in patients with idiopathic pulmonary fibrosis (IPF) on antifibrotic treatment. Respiratory Research, 2021, 22, 98.	1.4	21
21	The Diagnostic Yield of the Multidisciplinary Discussion in Patients With COVID-19 Pneumonia. Frontiers in Medicine, 2021, 8, 637872.	1.2	5
22	Critical Review of the Evolution of Extracellular Vesiclesâ€™ Knowledge: From 1946 to Today. International Journal of Molecular Sciences, 2021, 22, 6417.	1.8	64
23	Genetics in sarcoidosis. Current Opinion in Pulmonary Medicine, 2021, 27, 423-429.	1.2	17
24	Idiopathic pulmonary fibrosis: Disease mechanisms and drug development. , 2021, 222, 107798.		216
25	Fibrotic lung disease: A molecular glimpse into severe Covid-19?. EBioMedicine, 2021, 69, 103470.	2.7	4
26	Pulmonary Sarcoidosis: Diagnosis and Differential Diagnosis. Diagnostics, 2021, 11, 1558.	1.3	20
27	Disease Severity and Prognosis of SARS-CoV-2 Infection in Hospitalized Patients Is Not Associated With Viral Load in Nasopharyngeal Swab. Frontiers in Medicine, 2021, 8, 714221.	1.2	9
28	Early diagnosis of fibrotic interstitial lung disease: challenges and opportunities. Lancet Respiratory Medicine,the, 2021, 9, 1065-1076.	5.2	55
29	GED-0507 attenuates lung fibrosis by counteracting myofibroblast transdifferentiation in vivo and in vitro. PLoS ONE, 2021, 16, e0257281.	1.1	5
30	Subclinical liver fibrosis in patients with idiopathic pulmonary fibrosis. Internal and Emergency Medicine, 2021, 16, 349-357.	1.0	5
31	The Role of Bronchoscopy in the Diagnosis and Management of Patients with SARS-Cov-2 Infection. Diagnostics, 2021, 11, 1938.	1.3	3
32	Massive lung calcifications in a four times renal transplanted patient: the fight against dialysis, hyper and hypoparathyroidism. Minerva Endocrinology, 2021, , .	0.6	0
33	Characteristics and Prognostic Factors of Pulmonary Fibrosis After COVID-19 Pneumonia. Frontiers in Medicine, 2021, 8, 823600.	1.2	20
34	Mortality and Respiratory-Related Hospitalizations in Idiopathic Pulmonary Fibrosis Not Treated With Antifibrotics. Frontiers in Medicine, 2021, 8, 802989.	1.2	8
35	Genome-Wide Association Studies in Idiopathic Pulmonary Fibrosis: Bridging the Gap between Sequence and Consequence. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 508-509.	2.5	2
36	Challenges in Cardiac and PulmonaryÂSarcoidosis. Journal of the American College of Cardiology, 2020, 76, 1878-1901.	1.2	119

#	Article	IF	Citations
37	ERS International Congress, Madrid, 2019: highlights from the Interstitial Lung Diseases Assembly. ERJ Open Research, 2020, 6, 00143-2020.	1.1	0
38	Hypersensitivity pneumonitis. Nature Reviews Disease Primers, 2020, 6, 65.	18.1	75
39	Looking into the future of sarcoidosis: what is next for treatment?. Current Opinion in Pulmonary Medicine, 2020, 26, 598-607.	1.2	10
40	Clinical Presentations, Pathogenesis, and Therapy of Sarcoidosis: State of the Art. Journal of Clinical Medicine, 2020, 9, 2363.	1.0	28
41	Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities. Lancet Respiratory Medicine,the, 2020, 8, 925-934.	5.2	198
42	Clinical Features and Chest Imaging as Predictors of Intensity of Care in Patients with COVID-19. Journal of Clinical Medicine, 2020, 9, 2990.	1.0	20
43	Pulmonary fibrosis secondary to COVID-19: a call to arms?. Lancet Respiratory Medicine,the, 2020, 8, 750-752.	5.2	404
44	Shedding light on developmental drugs for idiopathic pulmonary fibrosis. Expert Opinion on Investigational Drugs, 2020, 29, 797-808.	1.9	8
45	GED-0507 is a novel potential antifibrotic treatment option for pulmonary fibrosis. Cellular and Molecular Immunology, 2020, 17, 1272-1274.	4.8	4
46	Acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF): an overview of current and future therapeutic strategies. Expert Review of Respiratory Medicine, 2020, 14, 405-414.	1.0	19
47	Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1146-1153.	2.5	60
48	The Role of the Lungâ€™s Microbiome in the Pathogenesis and Progression of Idiopathic Pulmonary Fibrosis. International Journal of Molecular Sciences, 2019, 20, 5618.	1.8	41
49	High-Resolution CT Change over Time in Patients with Idiopathic Pulmonary Fibrosis on Antifibrotic Treatment. Journal of Clinical Medicine, 2019, 8, 1469.	1.0	17
50	The Ariane-IPF ERS Clinical Research Collaboration: seeking collaboration through launch of a federation of European registries on idiopathic pulmonary fibrosis. European Respiratory Journal, 2019, 53, 1900539.	3.1	8
51	Endobronchial ultrasoundâ€guided transbronchial needle aspiration in sarcoidosis: Beyond the diagnostic yield. Respirology, 2019, 24, 531-542.	1.3	28
52	High-Resolution Computed Tomography (HRCT) Reflects Disease Progression in Patients with Idiopathic Pulmonary Fibrosis (IPF): Relationship with Lung Pathology. Journal of Clinical Medicine, 2019, 8, 399.	1.0	14
53	Research highlights from the 2018 ERS International Congress: interstitial lung diseases. ERJ Open Research, 2019, 5, 00215-2018.	1.1	5
54	Abandoning developmental silos. Current Opinion in Pulmonary Medicine, 2019, 25, 418-425.	1.2	2

#	Article	IF	Citations
55	Pretreatment rate of decay in forced vital capacity predicts long-term response to pirfenidone in patients with idiopathic pulmonary fibrosis. Scientific Reports, 2018, 8, 5961.	1.6	14
56	Pulmonary sarcoidosis. Lancet Respiratory Medicine,the, 2018, 6, 389-402.	5.2	544
57	Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH) Syndrome and Carcinoid Tumors With/Without NECH. American Journal of Surgical Pathology, 2018, 42, 646-655.	2.1	33
58	The Lung in Rheumatoid Arthritis. Arthritis and Rheumatology, 2018, 70, 1544-1554.	2.9	198
59	Sarcoidosis: is cryobiopsy not cool enough? â€“ Authors' reply. Lancet Respiratory Medicine,the, 2018, 6, e45.	5.2	3
60	The Management of Patients With Idiopathic Pulmonary Fibrosis. Frontiers in Medicine, 2018, 5, 148.	1.2	42
61	Genetics of idiopathic pulmonary fibrosis: from mechanistic pathways to personalised medicine. Journal of Medical Genetics, 2017, 54, 93-99.	1.5	50
62	Clinical trial research in focus: why do so many clinical trials fail in IPF?. Lancet Respiratory Medicine,the, 2017, 5, 372-374.	5.2	27
63	Acute exacerbations of interstitial lung disease. Current Opinion in Pulmonary Medicine, 2017, 23, 411-417.	1.2	26
64	Personalized medicine in interstitial lung diseases. Current Opinion in Pulmonary Medicine, 2017, 23, 231-236.	1.2	8
65	The role of macrophages in interstitial lung diseases. European Respiratory Review, 2017, 26, 170009.	3.0	39
66	Biopsy in idiopathic pulmonary fibrosis: back to the future. Expert Review of Respiratory Medicine, 2017, 11, 679-684.	1.0	3
67	Pirfenidone and mortality in idiopathic pulmonary fibrosis. Lancet Respiratory Medicine,the, 2017, 5, 3-5.	5.2	4
68	Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis: methodological concerns. European Respiratory Journal, 2016, 48, 1524-1526.	3.1	16
69	Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis. Lancet Respiratory Medicine,the, 2016, 4, 381-389.	5.2	189
70	Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia syndrome. European Respiratory Journal, 2016, 47, 1829-1841.	3.1	95
71	Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis. European Respiratory Journal, 2016, 47, 1776-1784.	3.1	61
72	Chickenpox-Related Multiple Pulmonary Granulomas: A Poorly Recognized Entity. Lung, 2016, 194, 329-330.	1.4	2

#	Article	IF	Citations
73	IPF in 2016: towards a better diagnosis. Lancet Respiratory Medicine,the, 2016, 4, 945-947.	5.2	3
74	Anti-acid treatment in patients with IPF: interpret results from post-hoc, subgroup, and exploratory analyses with great caution â€“ Authors' reply. Lancet Respiratory Medicine,the, 2016, 4, e48.	5.2	6
75	Interstitial Lung Disease in Children Younger Than 2 Years. Pediatrics, 2016, 137, .	1.0	44
76	Connective tissue diseases, multimorbidity and the ageing lung. European Respiratory Journal, 2016, 47, 1535-1558.	3.1	37
77	Hemoptysis and Progressive Dyspnea in a 67-Year-Old Woman with History of Renal Transplantation. American Journal of Respiratory and Critical Care Medicine, 2016, 193, e12-e13.	2.5	3
78	Immune Inflammation and Disease Progression in Idiopathic Pulmonary Fibrosis. PLoS ONE, 2016, 11, e0154516.	1.1	87
79	Personalized medicine in idiopathic pulmonary fibrosis. Current Opinion in Pulmonary Medicine, 2015, 21, 470-478.	1.2	46
80	Update on therapeutic management of idiopathic pulmonary fibrosis. Therapeutics and Clinical Risk Management, 2015, 11, 359.	0.9	51
81	Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives. BioMed Research International, 2015, 2015, 1-10.	0.9	60
82	Idiopathic pulmonary fibrosis: An update. Annals of Medicine, 2015, 47, 15-27.	1.5	97
83	Pharmacological treatment of idiopathic pulmonary fibrosis: an update. Drug Discovery Today, 2015, 20, 514-524.	3.2	26
84	Sarcoidosis: a Critical Review of History and Milestones. Clinical Reviews in Allergy and Immunology, 2015, 49, 1-5.	2.9	58
85	Novel Treatments for Idiopathic Pulmonary Fibrosis. American Journal of Medicine, 2015, 128, 447-449.	0.6	9
86	Immunogenetics of Disease-Causing Inflammation in Sarcoidosis. Clinical Reviews in Allergy and Immunology, 2015, 49, 19-35.	2.9	50
87	New guideline on treatment of idiopathic pulmonary fibrosis. Lancet Respiratory Medicine,the, 2015, 3, e31-e32.	5.2	4
88	Classification of different patterns of pulmonary adenocarcinomas. Expert Review of Respiratory Medicine, 2015, 9, 571-586.	1.0	23
89	Genetics of Sarcoidosis. Seminars in Respiratory and Critical Care Medicine, 2014, 35, 296-306.	0.8	49
90	Differential diagnosis of usual interstitial pneumonia: when is it truly idiopathic?. European Respiratory Review, 2014, 23, 308-319.	3.0	99

#	Article	IF	Citations
91	Imaging aspects of the diagnosis of sarcoidosis. European Radiology, 2014, 24, 807-816.	2.3	42
92	Genetic determinants of pulmonary fibrosis: evolving concepts. Lancet Respiratory Medicine,the, 2014, 2, 416-428.	5.2	66
93	Accuracy of Individual Variables in the Monitoring of Long-term Change in Pulmonary Sarcoidosis as Judged by Serial High-Resolution CT Scan Data. Chest, 2014, 145, 101-107.	0.4	38
94	Recent advances in the genetics of sarcoidosis. Journal of Medical Genetics, 2013, 50, 290-297.	1.5	74
95	Long-term macrolide treatment for chronic respiratory disease. European Respiratory Journal, 2013, 42, 239-251.	3.1	124
96	Sarcoidosis: Challenging Diagnostic Aspects of an Old Disease. American Journal of Medicine, 2012, 125, 118-125.	0.6	43
97	Genetic testing in diffuse parenchymal lung disease. Orphanet Journal of Rare Diseases, 2012, 7, 79.	1.2	8
98	Sarcoidosis HLA class II genotyping distinguishes differences of clinical phenotype across ethnic groups. Human Molecular Genetics, 2010, 19, 4100-4111.	1.4	121
99	Non-steroid agents for idiopathic pulmonary fibrosis. The Cochrane Library, 2010, , CD003134.	1.5	103